Reimbursement Review Reports


( Last Updated : October 2, 2022)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Anoro Ellipta Umeclidinium/vilanterol Chronic obstructive pulmonary disease List with criteria/condition Complete
Apidra Insulin glulisine Diabetes, Mellitus (Type 1 & 2) List in a similar manner to other drugs in class Complete
Apprilon Doxycycline monohydrate Rosacea Do not list Complete
Aptiom Eslicarbazepine acetate Epilepsy, partial-onset seizures List with criteria/condition Complete
Aptivus Tipranavir HIV infection List with clinical criteria and/or conditions Complete
Arbesda RespiClick fluticasone propionate / salmeterol xinafoate Asthma Reimburse with clinical criteria and/or conditions Complete
Arnuity Ellipta Fluticasone furoate Asthma List with criteria/condition Complete
Arzerra Ofatumumab Chronic Lymphocytic Leukemia Do not reimburse Complete